JP2016511259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511259A5 JP2016511259A5 JP2015560377A JP2015560377A JP2016511259A5 JP 2016511259 A5 JP2016511259 A5 JP 2016511259A5 JP 2015560377 A JP2015560377 A JP 2015560377A JP 2015560377 A JP2015560377 A JP 2015560377A JP 2016511259 A5 JP2016511259 A5 JP 2016511259A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- taz1
- expression
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100009810 TAZ Human genes 0.000 claims description 17
- 108060004243 ZBTB18 Proteins 0.000 claims description 14
- 201000010874 syndrome Diseases 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 11
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 6
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 6
- 239000002327 cardiovascular agent Substances 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000003087 receptor blocking agent Substances 0.000 claims description 6
- XVTUQDWPJJBEHJ-KZCWQMDCSA-N tetrastearoyl cardiolipin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)CO[P@@](O)(=O)OCC(O)CO[P@](O)(=O)OC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC XVTUQDWPJJBEHJ-KZCWQMDCSA-N 0.000 claims description 6
- 206010060945 Bacterial infection Diseases 0.000 claims description 3
- 201000005943 Barth syndrome Diseases 0.000 claims description 3
- 210000004369 Blood Anatomy 0.000 claims description 3
- 208000005846 Cardiomyopathy Diseases 0.000 claims description 3
- 229940068811 Digitalis preparation Drugs 0.000 claims description 3
- 210000002027 Muscle, Skeletal Anatomy 0.000 claims description 3
- 210000003205 Muscles Anatomy 0.000 claims description 3
- 208000004235 Neutropenia Diseases 0.000 claims description 3
- 101700024972 TAZ Proteins 0.000 claims description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 3
- 210000002700 Urine Anatomy 0.000 claims description 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 3
- 239000004004 anti-anginal agent Substances 0.000 claims description 3
- 230000001396 anti-anti-diuretic Effects 0.000 claims description 3
- 230000000702 anti-platelet Effects 0.000 claims description 3
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 239000003524 antilipemic agent Substances 0.000 claims description 3
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 3
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- 201000008031 cardiomyopathy Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 230000003111 delayed Effects 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 230000001882 diuretic Effects 0.000 claims description 3
- 239000003527 fibrinolytic agent Substances 0.000 claims description 3
- 230000000297 inotrophic Effects 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 239000002516 radical scavenger Substances 0.000 claims description 3
- 230000001624 sedative Effects 0.000 claims description 3
- 239000000932 sedative agent Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000002889 sympathetic Effects 0.000 claims description 3
- 229960000103 thrombolytic agents Drugs 0.000 claims description 3
- 239000002396 thromboxane receptor blocking agent Substances 0.000 claims description 3
- 230000000261 vasodilator Effects 0.000 claims description 3
- 239000003071 vasodilator agent Substances 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- -1 cardioglycide Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000007634 remodeling Methods 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 230000000087 stabilizing Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 17
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
- 230000003203 everyday Effects 0.000 description 4
- 159000000021 acetate salts Chemical class 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
Description
本発明のまた別の態様は、以下のとおりであってもよい。
〔１〕バース症候群の治療または予防を必要とする対象におけるバース症候群を治療または予防するための方法であって、治療有効量のペプチドＤ−Ａｒｇ−２’６’−Ｄｍｔ−Ｌｙｓ−Ｐｈｅ−ＮＨ 2 またはその薬学的に許容される塩を、前記対象に投与する工程を含むことを特徴とする、方法。
〔２〕前記対象が、正常対照対象と比較して低下したレベルのＴＡＺ１発現を示す、前記〔１〕に記載の方法。
〔３〕前記ペプチドが、６週間以上にわたって毎日投与される、前記〔１〕〜〔２〕のいずれか一項に記載の方法。
〔４〕前記ペプチドが、１２週間以上にわたって毎日投与される、前記〔１〕〜〔３〕のいずれか一項に記載の方法。
〔５〕前記対象が、バース症候群を有すると診断されている、前記〔１〕〜〔４〕のいずれか一項に記載の方法。
〔６〕前記バース症候群が、心筋症、骨格筋異常、好中球減少症、発育の遅れ、虚弱筋緊張、尿及び血液中の有機酸の濃度上昇、ならびに頻繁な細菌感染症のうちの１つ以上を含む、前記〔５〕に記載の方法。
〔７〕前記対象がヒトである、前記〔１〕〜〔６〕のいずれか一項に記載の方法。
〔８〕前記ペプチドが、経口的に、局所的に、全身的に、静脈内に、皮下に、腹腔内に、または筋肉内に投与される、前記〔１〕〜〔７〕のいずれか一項に記載の方法。
〔９〕前記対象に心血管薬剤を、個別に、連続して、または同時に投与する工程を更に含む、前記〔１〕〜〔８〕のいずれか一項に記載の方法。
〔１０〕前記心血管薬剤が、抗不整脈剤、血管拡張剤、抗狭心症薬、副腎皮質ステロイド剤、心臓配糖体（ｃａｒｄｉｏｇｌｙｃｏｓｉｄｅ）、利尿剤、鎮静剤、アンギオテンシン変換酵素（ＡＣＥ）阻害剤、アンギオテンシンＩＩ拮抗薬、血栓溶解剤、カルシウムチャネル遮断薬、トロボキサン（ｔｈｒｏｂｏｘａｎｅ）受容体拮抗薬、ラジカルスカベンジャー、抗血小板薬、β−アドレナリン受容体遮断薬、α−受容体遮断薬、交感神経阻害剤、ジギタリス製剤、変力物質、及び抗高脂質血症薬からなる群から選択される、前記〔９〕に記載の方法。
〔１１〕前記薬学的に許容される塩が、酢酸塩またはトリフルオロ酢酸塩を含む、前記〔１〕〜〔１０〕のいずれか一項に記載の方法。
〔１２〕ＴＡＺ１の発現の上昇を必要とする哺乳類対象における前記ＴＡＺ１の発現を上昇させるための方法であって、治療有効量のペプチドＤ−Ａｒｇ−２’６’−Ｄｍｔ−Ｌｙｓ−Ｐｈｅ−ＮＨ 2 またはその薬学的に許容される塩を、前記対象に投与する工程を含むことを特徴とする、方法。
〔１３〕前記対象における前記ＴＡＺ１の発現が、正常対照対象における前記ＴＡＺ１発現のレベルより約２〜５倍少ない、前記〔１２〕に記載の方法。
〔１４〕前記ペプチドが、６週間以上にわたって毎日投与される、前記〔１２〕〜〔１３〕のいずれか一項に記載の方法。
〔１５〕前記ペプチドが、１２週間以上にわたって毎日投与される、前記〔１２〕〜〔１４〕のいずれか一項に記載の方法。
〔１６〕前記対象が、バース症候群を有すると診断されているか、バース症候群を有する疑いがあるか、またはバース症候群を有する危険性がある、前記〔１２〕〜〔１５〕のいずれか一項に記載の方法。
〔１７〕前記バース症候群が、心筋症、骨格筋異常、好中球減少症、発育の遅れ、虚弱筋緊張、尿及び血液中の有機酸の濃度上昇、ならびに頻繁な細菌感染症のうちの１つ以上を含む、前記〔１６〕に記載の方法。
〔１８〕前記対象がヒトである、前記〔１２〕〜〔１７〕のいずれか一項に記載の方法。
〔１９〕前記ペプチドが、経口的に、局所的に、全身的に、静脈内に、皮下に、腹腔内に、または筋肉内に投与される、前記〔１２〕〜〔１８〕のいずれか一項に記載の方法。
〔２０〕前記対象に心血管薬剤を、個別に、連続して、または同時に投与する工程を更に含む、前記〔１２〕〜〔１９〕のいずれか一項に記載の方法。
〔２１〕前記心血管薬剤が、抗不整脈剤、血管拡張剤、抗狭心症薬、副腎皮質ステロイド剤、心臓配糖体、利尿剤、鎮静剤、アンギオテンシン変換酵素（ＡＣＥ）阻害剤、アンギオテンシンＩＩ拮抗薬、血栓溶解剤、カルシウムチャネル遮断薬、トロボキサン（ｔｈｒｏｂｏｘａｎｅ）受容体拮抗薬、ラジカルスカベンジャー、抗血小板薬、β−アドレナリン受容体遮断薬、α−受容体遮断薬、交感神経阻害剤、ジギタリス製剤、変力物質、及び抗高脂質血症薬からなる群から選択される、前記〔２０〕に記載の方法。
〔２２〕前記薬学的に許容される塩が、酢酸塩またはトリフルオロ酢酸塩を含む、前記〔１２〕〜〔２２〕のいずれか一項に記載の方法。
〔２３〕正常対照対象と比較して低下したＴＡＺ１の発現を有する哺乳類対象におけるバース症候群の危険性を減少させるための方法であって、治療有効量のペプチドＤ−Ａｒｇ−２’６’−Ｄｍｔ−Ｌｙｓ−Ｐｈｅ−ＮＨ 2 またはその薬学的に許容される塩を、前記対象に投与する工程を含むことを特徴とする、方法。
〔２４〕バース症候群を有するか、またはバース症候群を有する疑いのある哺乳類対象におけるカルジオリピンリモデリングを安定化するための方法であって、治療有効量のペプチドＤ−Ａｒｇ−２’６’−Ｄｍｔ−Ｌｙｓ−Ｐｈｅ−ＮＨ 2 またはその薬学的に許容される塩を、前記対象に投与する工程を含むことを特徴とする、方法。
〔２５〕前記哺乳類対象が、正常対照対象と比較して減少したＴＡＺ１の発現を有する、前記〔２４〕に記載の方法。
〔２６〕前記カルジオリピンが、１８：２のカルジオリピン種である、前記〔２４〕に記載の方法。
他の実施形態は、以下の特許請求の範囲内に説明される。
Another aspect of the present invention may be as follows.
[1] A method for treating or preventing Bath syndrome in a subject in need of treatment or prevention of Bath syndrome, comprising a therapeutically effective amount of peptide D-Arg-2′6′-Dmt-Lys-Phe-NH 2. A method comprising administering 2 or a pharmaceutically acceptable salt thereof to said subject.
[2] The method of [1], wherein the subject exhibits a reduced level of TAZ1 expression compared to a normal control subject.
[3] The method according to any one of [1] to [2], wherein the peptide is administered every day for 6 weeks or more.
[4] The method according to any one of [1] to [3], wherein the peptide is administered every day for 12 weeks or more.
[5] The method according to any one of [1] to [4], wherein the subject is diagnosed as having Barth syndrome.
[6] The Bath syndrome is one of cardiomyopathy, skeletal muscle abnormality, neutropenia, delayed development, weak muscle tone, increased concentration of organic acids in urine and blood, and frequent bacterial infections The method according to [5] above, comprising two or more.
[7] The method according to any one of [1] to [6], wherein the subject is a human.
[8] The peptide according to any one of [1] to [7], wherein the peptide is administered orally, topically, systemically, intravenously, subcutaneously, intraperitoneally, or intramuscularly. The method according to item.
[9] The method according to any one of [1] to [8], further comprising the step of administering cardiovascular drugs individually, sequentially, or simultaneously to the subject.
[10] The cardiovascular agent is an antiarrhythmic agent, vasodilator, antianginal agent, corticosteroid, cardioglycide, diuretic, sedative, angiotensin converting enzyme (ACE) inhibitor , Angiotensin II antagonist, thrombolytic agent, calcium channel blocker, thromboxane receptor antagonist, radical scavenger, antiplatelet agent, β-adrenergic receptor blocker, α-receptor blocker, sympathetic inhibitor The method according to [9], wherein the method is selected from the group consisting of: a digitalis preparation, an inotropic substance, and an antihyperlipidemic drug.
[11] The method according to any one of [1] to [10], wherein the pharmaceutically acceptable salt includes acetate or trifluoroacetate.
[12] A method for increasing the expression of TAZ1 in a mammalian subject in need of increased expression of TAZ1, comprising a therapeutically effective amount of peptide D-Arg-2′6′-Dmt-Lys-Phe-NH 2. A method comprising administering 2 or a pharmaceutically acceptable salt thereof to said subject.
[13] The method of [12], wherein the expression of TAZ1 in the subject is about 2 to 5 times less than the level of TAZ1 expression in a normal control subject.
[14] The method according to any one of [12] to [13], wherein the peptide is administered every day for 6 weeks or more.
[15] The method according to any one of [12] to [14], wherein the peptide is administered every day for 12 weeks or more.
[16] In any one of the above [12] to [15], wherein the subject is diagnosed as having Bath syndrome, suspected of having Bath syndrome, or at risk of having Bath syndrome The method described.
[17] The Barth syndrome is one of cardiomyopathy, skeletal muscle abnormality, neutropenia, delayed development, weak muscle tone, increased concentrations of organic acids in urine and blood, and frequent bacterial infections The method according to [16] above, comprising two or more.
[18] The method according to any one of [12] to [17], wherein the subject is a human.
[19] Any one of the above [12] to [18], wherein the peptide is administered orally, topically, systemically, intravenously, subcutaneously, intraperitoneally, or intramuscularly. The method according to item.
[20] The method according to any one of [12] to [19], further comprising the step of administering the cardiovascular agent individually, sequentially or simultaneously to the subject.
[21] The cardiovascular agent is an antiarrhythmic agent, vasodilator, antianginal agent, corticosteroid, heart glycoside, diuretic, sedative, angiotensin converting enzyme (ACE) inhibitor, angiotensin II Antagonist, thrombolytic agent, calcium channel blocker, thromboxane receptor antagonist, radical scavenger, antiplatelet agent, β-adrenergic receptor blocker, α-receptor blocker, sympathetic inhibitor, digitalis preparation The method according to [20] above, wherein the method is selected from the group consisting of an inotropic substance and an antihyperlipidemic agent.
[22] The method according to any one of [12] to [22], wherein the pharmaceutically acceptable salt includes an acetate salt or a trifluoroacetate salt.
[23] A method for reducing the risk of Bath syndrome in a mammalian subject having reduced expression of TAZ1 as compared to a normal control subject, comprising a therapeutically effective amount of peptide D-Arg-2′6′-Dmt -Lys-Phe-NH 2 or a pharmaceutically acceptable salt thereof, characterized in that it comprises the step of administering to said subject methods.
[24] A method for stabilizing cardiolipin remodeling in a mammalian subject having or suspected of having Bath syndrome, comprising a therapeutically effective amount of peptide D-Arg-2′6′-Dmt- A method comprising administering to the subject Lys-Phe-NH 2 or a pharmaceutically acceptable salt thereof.
[25] The method described in [24] above, wherein the mammalian subject has decreased expression of TAZ1 compared to a normal control subject.
[26] The method according to [24] above, wherein the cardiolipin is an 18: 2 cardiolipin species.
Other embodiments are set forth within the following claims.
Claims (16)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019080101A JP6918046B2 (en) | 2013-03-01 | 2019-04-19 | Methods and compositions for the prevention or treatment of Bath syndrome |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771534P | 2013-03-01 | 2013-03-01 | |
| US201361771642P | 2013-03-01 | 2013-03-01 | |
| US61/771,534 | 2013-03-01 | ||
| US61/771,642 | 2013-03-01 | ||
| US201361839753P | 2013-06-26 | 2013-06-26 | |
| US61/839,753 | 2013-06-26 | ||
| PCT/US2014/019622 WO2014134554A1 (en) | 2013-03-01 | 2014-02-28 | Methods and compositions for the prevention or treatment of barth syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019080101A Division JP6918046B2 (en) | 2013-03-01 | 2019-04-19 | Methods and compositions for the prevention or treatment of Bath syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511259A JP2016511259A (en) | 2016-04-14 |
| JP2016511259A5 true JP2016511259A5 (en) | 2017-04-06 |
| JP6518197B2 JP6518197B2 (en) | 2019-05-22 |
Family
ID=51428869
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560377A Active JP6518197B2 (en) | 2013-03-01 | 2014-02-28 | Methods and compositions for the prevention or treatment of Barth syndrome |
| JP2019080101A Active JP6918046B2 (en) | 2013-03-01 | 2019-04-19 | Methods and compositions for the prevention or treatment of Bath syndrome |
| JP2021019903A Active JP7072692B2 (en) | 2013-03-01 | 2021-02-10 | Methods and compositions for the prevention or treatment of Barth syndrome |
| JP2022077425A Active JP7381652B2 (en) | 2013-03-01 | 2022-05-10 | Methods and compositions for preventing or treating Barth syndrome |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019080101A Active JP6918046B2 (en) | 2013-03-01 | 2019-04-19 | Methods and compositions for the prevention or treatment of Bath syndrome |
| JP2021019903A Active JP7072692B2 (en) | 2013-03-01 | 2021-02-10 | Methods and compositions for the prevention or treatment of Barth syndrome |
| JP2022077425A Active JP7381652B2 (en) | 2013-03-01 | 2022-05-10 | Methods and compositions for preventing or treating Barth syndrome |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US9687519B2 (en) |
| EP (2) | EP3626252A1 (en) |
| JP (4) | JP6518197B2 (en) |
| CN (3) | CN115990241A (en) |
| CA (1) | CA2916880C (en) |
| DK (1) | DK2961420T3 (en) |
| ES (1) | ES2750258T3 (en) |
| HU (1) | HUE046924T2 (en) |
| WO (1) | WO2014134554A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE046924T2 (en) | 2013-03-01 | 2020-03-30 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
| JP6839490B2 (en) | 2013-03-01 | 2021-03-10 | ステルス バイオセラピューティックス コープ | Methods for the treatment of mitochondrial diseases |
| US10047395B2 (en) * | 2013-06-26 | 2018-08-14 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
| US9550981B2 (en) | 2014-01-22 | 2017-01-24 | University Of Washington | Modified tafazzin proteins and methods of making and using the same |
| US10086040B2 (en) | 2014-12-12 | 2018-10-02 | University Of Washington | Methods for treating and preventing cardiomyopathy with a fusion protein of tafazzin and a cellular permeability peptide |
| WO2018104172A1 (en) | 2016-12-06 | 2018-06-14 | Centre National De La Recherche Scientifique (Cnrs) | Compounds for treating barth syndrome |
| US11034724B2 (en) | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| EP1423507A2 (en) | 2001-08-06 | 2004-06-02 | Vanderbilt University | System and methods for discriminating an agent |
| BRPI0105509B8 (en) | 2001-11-05 | 2021-05-25 | Univ Minas Gerais | formulations of the angiotensin- (1-7) peptide using cyclodextrins, liposomes and the plga polymer |
| SI1599216T1 (en) | 2003-02-04 | 2014-02-28 | Cornell Research Foundation, Inc. | Methods for preventing mitochondrial permeability transition |
| DK2656854T3 (en) | 2003-02-04 | 2015-07-06 | Cornell Res Foundation Inc | Applications of an aromatic-cationic peptide |
| EP1597276A4 (en) * | 2003-02-10 | 2006-11-29 | Autogen Res Pty Ltd | Therapeutic molecules |
| WO2005023274A1 (en) | 2003-09-05 | 2005-03-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium |
| CA2971931C (en) | 2004-01-23 | 2019-01-08 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| US8500720B2 (en) | 2005-05-09 | 2013-08-06 | Medtronic, Inc | Method and apparatus for treatment of cardiac disorders |
| US20070265216A1 (en) * | 2005-10-05 | 2007-11-15 | Gross Richard W | Enhanced medical treatment in diabetic cardiomyopathy |
| AU2007237899A1 (en) | 2006-04-18 | 2007-10-25 | Cortendo Invest, Ab | Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions |
| EP2641617A1 (en) | 2007-05-02 | 2013-09-25 | THE McLEAN HOSPITAL CORPORATION | Methods and compositions for mitochondrial replacement therapy |
| US20080318909A1 (en) | 2007-06-14 | 2008-12-25 | Sparagna Genevieve C | Use Of Linoleic Compounds Against Heart Failure |
| WO2008156654A2 (en) | 2007-06-15 | 2008-12-24 | Massachusetts Institute Of Technology | Cytoskeleton modulators for treating metabolic disorders |
| WO2009108695A2 (en) * | 2008-02-26 | 2009-09-03 | Cornell University | Methods for prevention and treatment of acute renal injury |
| US20110197294A1 (en) | 2008-06-04 | 2011-08-11 | Gottlieb Roberta A | Compositions and methods for restoring mitochondrial electron transfer function |
| EA020091B1 (en) | 2008-08-07 | 2014-08-29 | Ипсен Фарма С.А.С. | Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal |
| WO2010120431A2 (en) | 2009-03-20 | 2010-10-21 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Methods for the prevention and treatment of burn injuries and secondary complications |
| EP2419513A2 (en) | 2009-04-17 | 2012-02-22 | The Salk Institute For Biological Studies | Regulation of aging by modulation of mitochondrial function |
| US20120046363A1 (en) | 2009-05-11 | 2012-02-23 | University Of Maryland, Baltimore | Docosahexaenoic acid for the treatment of heart failure |
| DK2464371T3 (en) | 2009-08-12 | 2016-06-27 | Univ Cornell | Methods for preventing or treating metabolic syndrome |
| CA2772094C (en) * | 2009-08-24 | 2018-04-03 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
| EP2485749A4 (en) | 2009-10-05 | 2013-07-24 | Univ Cornell | Methods for the prevention or treatment of heart failure |
| US8719939B2 (en) | 2009-12-31 | 2014-05-06 | Mcafee, Inc. | Malware detection via reputation system |
| WO2011082324A1 (en) | 2009-12-31 | 2011-07-07 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of vessel occlusion injury |
| WO2011082355A1 (en) | 2009-12-31 | 2011-07-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| JP4643749B1 (en) | 2010-02-03 | 2011-03-02 | 昭和電工株式会社 | Treatment liquid for forming oxidation-resistant film on surface coated cermet members |
| EP3511012A1 (en) * | 2010-02-26 | 2019-07-17 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
| JP2013522311A (en) | 2010-03-15 | 2013-06-13 | ステルス ペプチドズ インターナショナル インコーポレイテッド | Combination therapy with cyclosporine and aromatic-cationic peptide |
| WO2011139992A1 (en) | 2010-05-03 | 2011-11-10 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| WO2012009171A2 (en) | 2010-07-15 | 2012-01-19 | The Schepens Eye Research Institute, Inc. | Compositions and methods of treatment of corneal endothelium disorders |
| BR112013002877A2 (en) | 2010-08-06 | 2016-05-31 | Edison Pharmaceuticals Inc | treatment of mitochondrial diseases with naphthoquinones |
| WO2012019032A1 (en) | 2010-08-06 | 2012-02-09 | Ampere Life Sciences, Inc. | Treatment of mitochondrial diseases with vitamin k |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| CN109705192A (en) * | 2011-03-24 | 2019-05-03 | 康奈尔大学 | Aromatic-cationic peptides and application thereof |
| CN106913860A (en) | 2011-09-29 | 2017-07-04 | 梅约医学教育与研究基金会 | Aromatic-cationic peptide and use their method |
| WO2013059071A1 (en) | 2011-10-17 | 2013-04-25 | Cornell University | Aromatic-cationic peptides and uses of same |
| JP2014532628A (en) * | 2011-10-21 | 2014-12-08 | ステムジェニクス・インコーポレイテッド | Functional nanoparticles for intracellular transport of bioactive molecules |
| CN104244964A (en) | 2012-02-22 | 2014-12-24 | 康肽德生物医药技术有限公司 | Methods and compositions for preventing or treating ophthalmic conditions |
| AU2013222237B2 (en) * | 2012-02-23 | 2017-10-05 | Cornell University | Aromatic-cationic peptides and uses of same |
| WO2014059029A1 (en) | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function |
| EP2908839B1 (en) * | 2012-10-22 | 2019-08-21 | Stealth Peptides International, Inc. | Methods for reducing risks associated with heart failure and factors associated therewith |
| HUE046924T2 (en) | 2013-03-01 | 2020-03-30 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
| JP6839490B2 (en) | 2013-03-01 | 2021-03-10 | ステルス バイオセラピューティックス コープ | Methods for the treatment of mitochondrial diseases |
| US10047395B2 (en) * | 2013-06-26 | 2018-08-14 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
-
2014
- 2014-02-28 HU HUE14756991A patent/HUE046924T2/en unknown
- 2014-02-28 CN CN202211634590.4A patent/CN115990241A/en active Pending
- 2014-02-28 EP EP19190165.1A patent/EP3626252A1/en active Pending
- 2014-02-28 CA CA2916880A patent/CA2916880C/en active Active
- 2014-02-28 EP EP14756991.7A patent/EP2961420B1/en active Active
- 2014-02-28 JP JP2015560377A patent/JP6518197B2/en active Active
- 2014-02-28 ES ES14756991T patent/ES2750258T3/en active Active
- 2014-02-28 WO PCT/US2014/019622 patent/WO2014134554A1/en active Application Filing
- 2014-02-28 CN CN201480022767.2A patent/CN105407906A/en active Pending
- 2014-02-28 US US14/771,408 patent/US9687519B2/en active Active
- 2014-02-28 CN CN202211635437.3A patent/CN115990242A/en active Pending
- 2014-02-28 DK DK14756991.7T patent/DK2961420T3/en active
-
2017
- 2017-06-19 US US15/626,255 patent/US11083771B2/en active Active
-
2019
- 2019-04-19 JP JP2019080101A patent/JP6918046B2/en active Active
-
2020
- 2020-07-15 US US16/929,370 patent/US11083772B2/en active Active
-
2021
- 2021-02-10 JP JP2021019903A patent/JP7072692B2/en active Active
- 2021-07-09 US US17/371,475 patent/US11771734B2/en active Active
-
2022
- 2022-05-10 JP JP2022077425A patent/JP7381652B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016511259A5 (en) | ||
| JP7175506B2 (en) | Angiotensin II used alone or in combination for the treatment of hypotension | |
| Schmidinger | Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors | |
| Mentz et al. | The past, present and future of renin–angiotensin aldosterone system inhibition | |
| JP2020002171A5 (en) | ||
| JP2022116008A5 (en) | ||
| BR0315315A (en) | Method for treating, preventing or controlling a myelodysplastic syndrome, method for reducing or preventing an adverse effect associated with the administration of a second active ingredient to a patient suffering from a myelodysplastic syndrome, pharmaceutical composition, single unit dosage form, and kit | |
| RU2016148364A (en) | TREATMENT OF COMPLICATIONS OF CHRONIC LIVER DISEASES | |
| JP2020500164A5 (en) | ||
| JP2010509258A (en) | Use of adenosine antagonists | |
| Dorian et al. | Upstream therapies to prevent atrial fibrillation | |
| JP2016517401A5 (en) | ||
| JP2020520923A5 (en) | ||
| JP2016522196A5 (en) | ||
| JP2018522891A5 (en) | ||
| JP2017519762A5 (en) | ||
| BR112021009627A2 (en) | application of chidamide in combination with r-chop, and drug combination | |
| Smithies et al. | Role of the tissue factor pathway in the pathogenesis and management of multiple organ failure | |
| Evasio et al. | Effect of nolomirole on monocrotaline-induced heart failure | |
| Tavakoli et al. | Modulated hemodynamic response to clonidine in bile duct-ligated rats: the role of nitric oxide | |
| JP2017514834A (en) | Combination therapy for treating HCV infection | |
| JP2011528345A (en) | Use of idrabiotaparinux to reduce bleeding rates during antithrombotic therapy | |
| Jiao et al. | e0155 Smoking treatment increase serum AGEs Level and have effects on expression of ICAM-1 in vascular endothelial cells of rat | |
| JP2018533570A5 (en) | ||
| Snehal Kulkarni | Evidence-based Management of Pulmonary Arterial Hypertension |